Creator: Help Dementia Editorial Team
Published: 2026-04-03T08:34:00

Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.

Dementia screening sits at the center of this dementia and brain health question.

Yes, Congress is actively considering legislation called the Alzheimer’s Screening and Prevention (ASAP) Act that would fundamentally change how dementia screening is covered for seniors. Under current Medicare law, doctors cannot order dementia screening blood tests for people who have no existing symptoms—even if they’re concerned about their risk. The ASAP Act would remove this barrier, allowing Medicare to cover FDA-approved blood biomarker tests for the early detection of Alzheimer’s and other dementias for any eligible senior who wants one. Imagine a 72-year-old who’s noticed occasional memory lapses but hasn’t been officially diagnosed with dementia: under today’s rules, Medicare wouldn’t pay for a blood test to check for early signs.

The ASAP Act would change that. This bipartisan legislation, sponsored by representatives from both parties in the House and Senate, directly addresses a growing problem in American healthcare. As many as half of the estimated 7 million Americans living with Alzheimer’s disease go undiagnosed, meaning their condition isn’t identified until symptoms are severe. By making screening accessible and covered, the bill aims to catch dementia earlier, when interventions may be most effective. This article explains what the ASAP Act would actually do, how it works, what it covers, and what happens next as Congress considers it.

How the ASAP Act Would Change Medicare’s Coverage Rules for Dementia Screening
The Blood Biomarker Tests That Would Be Covered
Widespread Support from Doctors, Researchers, and Patient Advocates
How Seniors Would Actually Access These Tests Under the ASAP Act
Important Limitations and Considerations
The Undiagnosed Population This Bill Could Help
What Happens Next and Why This Matters Now
Conclusion

How the ASAP Act Would Change Medicare’s Coverage Rules for Dementia Screening

The current Medicare policy creates an artificial ceiling on dementia detection. Medicare covers dementia screening tests, but only after a senior has already shown symptoms or cognitive decline. This backward-looking approach means the tests come too late for early intervention. The ASAP Act creates what lawmakers call a “pathway” for Medicare coverage of blood biomarker tests used for early detection, removing the requirement that people already have obvious symptoms before being tested.

The bill was introduced in the House on November 19, 2025, by Representatives Vern Buchanan (R-FL) and Paul Tonko (D-NY), with companion legislation in the Senate led by Senators Susan Collins (R-ME), Catherine Cortez Masto (D-NV), Shelley Moore Capito (R-WV), and Mark Warner (D-VA). The bipartisan nature of the sponsorship matters—it signals this isn’t a partisan issue but a genuine public health concern. However, it’s important to note that “free” in this context means covered by Medicare without the current restrictions, not literally free for all seniors. Seniors would still be responsible for any copayments or coinsurance associated with Medicare Part B benefits, depending on their plan.

How the ASAP Act Would Change Medicare's Coverage Rules for Dementia Screening

The Blood Biomarker Tests That Would Be Covered

Blood biomarker tests represent a major breakthrough in dementia detection. Rather than relying on cognitive assessments that can be subjective or only catch problems after they’re obvious, these blood tests look for specific proteins and markers associated with Alzheimer’s disease—namely phosphorylated tau and amyloid-beta. A senior could get a simple blood draw in their primary care doctor’s office, with results revealing whether the disease process is already underway in their brain, even if they feel and function normally. The FDA approved the first blood-based biomarker test for primary care use earlier in 2025, but the problem is that Medicare currently won’t reimburse for it.

This creates a strange situation: a test exists, doctors can order it, but it becomes expensive and out of reach for many seniors. The ASAP Act would solve this by establishing a clear pathway for Medicare coverage of FDA-approved blood biomarker tests. However, there’s an important caveat: coverage doesn’t happen instantly after the bill passes. Medicare would need to establish specific clinical policies, billing codes, and reimbursement rates for these tests, which can take months or even years to implement fully.

Widespread Support from Doctors, Researchers, and Patient Advocates

What makes the ASAP Act noteworthy is the breadth of support behind it. By March 2026, more than 459 leading organizations and researchers—including the Alzheimer’s Association and the Alzheimer’s Impact Movement—had endorsed the legislation. This coalition includes geriatricians, neurologists, primary care physicians, research institutions, and patient advocacy groups, all saying the same thing: early detection saves lives, and screening shouldn’t be blocked by insurance red tape.

The Alzheimer’s Association’s support is particularly significant because this organization has long advocated for earlier intervention in dementia care. Their research shows that identifying Alzheimer’s in its earliest stages—before significant cognitive symptoms appear—allows people to work with their doctors on strategies to potentially slow decline. Doctors and researchers understand something that policy sometimes misses: once someone has obvious dementia symptoms, crucial time for intervention has already passed. The widespread support from so many organizations suggests this isn’t a niche concern but reflects genuine medical consensus about what patients need.

Widespread Support from Doctors, Researchers, and Patient Advocates

How Seniors Would Actually Access These Tests Under the ASAP Act

If the ASAP Act becomes law and Medicare establishes the necessary coverage policies, the process would be straightforward for most seniors. A person on Medicare Part B would discuss their dementia risk with their primary care doctor—whether because they have family history, are noticing subtle memory changes, or simply want peace of mind. The doctor could order a blood biomarker test. The lab would process it, and Medicare would cover the cost (minus any applicable beneficiary cost-sharing). Seniors wouldn’t need special referrals or pre-approval from their insurance company the way some other tests require.

However, access depends on several factors working in concert. First, Medicare needs to actually establish the coverage policies and billing codes—something Congress can’t force to happen instantly. Second, seniors need doctors willing to order the test and comfortable interpreting the results, which brings us to a related piece of legislation. The AADAPT Act (Accelerating Access to Dementia & Alzheimer’s Provider Training Act), reintroduced by Senators Capito and Klobuchar in March 2026, aims to expand training for primary care doctors on dementia detection and treatment. Without that training component, some primary care doctors might be hesitant to order tests they don’t feel equipped to discuss with patients, even if Medicare covers them.

Important Limitations and Considerations

The ASAP Act addresses insurance coverage, but it doesn’t solve every barrier to early dementia detection. Access to healthcare itself remains an issue—seniors who don’t have regular contact with a doctor, or who live in rural areas with limited specialist availability, won’t benefit from coverage improvements if they can’t see someone who can order the test. Additionally, the bill doesn’t address what happens after someone gets screened and learns they have biomarker evidence of early disease. If you test positive for Alzheimer’s disease in its asymptomatic stage, you have limited treatment options beyond lifestyle modifications and possibly enrollment in research trials.

This creates an ethical question the medical community is still grappling with: Should we be screening for a condition we can’t yet cure? Another important limitation: these blood biomarker tests are primarily validated for detecting Alzheimer’s disease specifically, not all types of dementia. Vascular dementia, Lewy body dementia, and frontotemporal dementia are distinct conditions requiring different approaches. A blood test that comes back normal for Alzheimer’s markers doesn’t rule out other dementia causes. Seniors and their doctors need to understand this so they’re not falsely reassured by a negative Alzheimer’s test if other concerns exist.

Important Limitations and Considerations

The Undiagnosed Population This Bill Could Help

The scope of undiagnosed dementia in America is staggering. Of the approximately 7.1 million Americans living with Alzheimer’s disease, roughly half have not been diagnosed. That means 3.5 million or more people are living with cognitive decline that they, their families, and their doctors don’t recognize as disease. Some chalked it up to normal aging. Others rationalized the memory problems.

Still others had appointments on their calendar to see a neurologist but never made it. The ASAP Act’s goal is to shift this dynamic by making screening accessible in primary care settings where most seniors already have relationships with doctors. For many people, getting a diagnosis—even a worrisome one—is better than the uncertainty and denial that often precedes it. A diagnosis allows people to plan for the future, make financial and legal decisions while still able, inform family members, and participate in research or treatment trials. The blood biomarker test wouldn’t prevent disease, but it could provide the information that prompts action before problems become undeniable.

What Happens Next and Why This Matters Now

The ASAP Act is working its way through Congress as of early 2026. Like all legislation, it faces a long path: committee review, floor votes in both chambers, reconciling any differences, and presidential signature. The timeline is uncertain. What’s clear is that the medical and scientific community is unified in supporting earlier detection, which changes the political calculus.

Even in a polarized Congress, legislation that has bipartisan sponsorship and endorsement from hundreds of organizations has a better chance of moving forward. The timing is important because the science of dementia detection is advancing faster than policy. Blood biomarker tests exist and are being used privately, but gatekeeping based on insurance coverage creates a two-tiered system where wealthy seniors can pay out of pocket for screening while others can’t afford it. The ASAP Act aims to democratize access. Whether it passes or not, the conversation it’s sparked—about the importance of early detection, the role of primary care in dementia screening, and the need for better physician training—is shifting how the healthcare system thinks about Alzheimer’s disease.

Conclusion

Congress is seriously considering the Alzheimer’s Screening and Prevention (ASAP) Act, legislation that would remove current Medicare barriers to dementia screening for seniors. The bill would establish coverage for FDA-approved blood biomarker tests used to detect early Alzheimer’s disease, moving from a system that only screens people already showing symptoms to one that allows earlier detection. With broad bipartisan support in Congress and endorsement from over 459 medical organizations and researchers, the legislation reflects genuine medical consensus about what patients need.

If you’re a senior concerned about dementia risk, you don’t need to wait for the bill to pass to talk with your doctor about your concerns. You can discuss your family history, ask about your risk factors, and explore what screening options might be available to you now—many primary care doctors are already comfortable with these conversations. Stay informed as the ASAP Act progresses through Congress, and watch for updates about Medicare coverage policies once the bill becomes law, as implementation may take additional time.